What is he best known for?
The fields of study he is best known for:
His scientific interests lie mostly in Molecular biology, Biochemistry, Antigen, Sialyl-Lewis X and Monoclonal antibody. His Molecular biology research incorporates themes from Malignant transformation, Sulfotransferase, Cancer cell, Complementary DNA and Epitope. His study in Glycolipid, Transfection, High endothelial venules, Ceramide and Fatty acid is done as part of Biochemistry.
His Antigen research is multidisciplinary, incorporating elements of Teratocarcinoma and Fucose. His study in Sialyl-Lewis X is interdisciplinary in nature, drawing from both Endothelial stem cell and Lymphocyte homing receptor, Cell adhesion, E-selectin. His studies in Monoclonal antibody integrate themes in fields like Embryonic stem cell and Ganglioside.
His most cited work include:
- Glycosphingolipids as tumor-associated and differentiation markers. (557 citations)
- Stage-specific embryonic antigens (SSEA-3 and -4) are epitopes of a unique globo-series ganglioside isolated from human teratocarcinoma cells. (517 citations)
- Contribution of Carbohydrate Antigens Sialyl Lewis A and Sialyl Lewis X to Adhesion of Human Cancer Cells to Vascular Endothelium (505 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Molecular biology, Biochemistry, Antigen, Monoclonal antibody and Antibody. Reiji Kannagi works mostly in the field of Molecular biology, limiting it down to topics relating to Fucosyltransferase and, in certain cases, High endothelial venules, as a part of the same area of interest. His Biochemistry study incorporates themes from Sialyl-Lewis X and Selectin.
His Sialyl-Lewis X research focuses on subjects like Cancer cell, which are linked to E-selectin, Malignant transformation, Cell biology, Cell adhesion and Cancer stem cell. As a member of one scientific family, Reiji Kannagi mostly works in the field of Antigen, focusing on Cancer research and, on occasion, Internal medicine. The study incorporates disciplines such as Mucin, Recombinant DNA and Adenocarcinoma in addition to Monoclonal antibody.
He most often published in these fields:
- Molecular biology (37.32%)
- Biochemistry (35.57%)
- Antigen (25.66%)
What were the highlights of his more recent work (between 2008-2021)?
- Glycan (11.08%)
- Biochemistry (35.57%)
- Cell biology (9.91%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Glycan, Biochemistry, Cell biology, Immunology and Cancer research. His studies deal with areas such as Receptor, Sialic acid, Homing, SIGLEC and Cancer cell as well as Glycan. He has researched Cancer cell in several fields, including Sialyl-Lewis X, Molecular biology, Cell culture and Cell adhesion.
His work carried out in the field of Biochemistry brings together such families of science as Tumor hypoxia and Monoclonal antibody. The concepts of his Monoclonal antibody study are interwoven with issues in Epitope, Antigen, Cyst and Recombinant DNA. In his study, Pathology is inextricably linked to Metastasis, which falls within the broad field of Cancer research.
Between 2008 and 2021, his most popular works were:
- Glycosylation Changes in Cancer (162 citations)
- Transcription factors c-Myc and CDX2 mediate E-selectin ligand expression in colon cancer cells undergoing EGF/bFGF-induced epithelial–mesenchymal transition (118 citations)
- Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3high regulatory T cells in humans (95 citations)
In his most recent research, the most cited papers focused on:
Reiji Kannagi spends much of his time researching Glycan, Molecular biology, Biochemistry, Cell biology and Cancer cell. His work deals with themes such as Receptor, SIGLEC and Glycosylation, which intersect with Glycan. His Molecular biology study combines topics from a wide range of disciplines, such as Epidermal growth factor, Downregulation and upregulation, microRNA, Colorectal cancer and Gene silencing.
His Biochemistry study deals with Tumor hypoxia intersecting with Sphingomyelin, Ceramide synthase and Glycolipid. His Cell biology study integrates concerns from other disciplines, such as Vascular endothelial growth factor C, Vascular endothelial growth factor B, Angiogenesis and VEGF receptors. His research in Cancer cell intersects with topics in Sialyl-Lewis X, Cancer research and E-selectin.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
